piqray 200 mg compresse rivestite con film
novartis pharma schweiz ag - alpelisibum - compresse rivestite con film - alpelisibum 200 mg, cellulosum microcristallinum, mannitolum, carboxymethylamylum natricum un corrisp. sodio 0,84 mg, hypromellosum, magnesio stearas, Überzug: hypromellosum, macrogolum, talco, e 171, e 172, per compresso haze. - in combinazione con fulvestrant per il trattamento di hr-positivo, her2-negativo carcinoma mammario avanzato con mutazione pik3ca - synthetika
piqray
novartis europharm limited - alpelisib - neoplasie al seno - agenti antineoplastici - piqray è indicato in combinazione con fulvestrant per il trattamento di donne in postmenopausa e uomini, con recettore ormonale (hr)-positivo, human epidermal growth factor receptor 2 (her2)-negativo, localmente avanzato o metastatico cancro al seno con una mutazione pik3ca dopo progressione della malattia dopo terapia endocrina come monoterapia (vedere la sezione 5.
rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - agenti antineoplastici - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
copiktra
secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - agenti antineoplastici - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies. follicular lymphoma (fl) that is refractory to at least two prior systemic therapies.
camzyos 2.5 mg capsule rigide
bristol-myers squibb sa - mavacamtenum - capsule rigide - mavacamtenum 2.5 mg, silica colloidalis hydrica, mannitolum, hypromellosum, carmellosum natricum conexum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (nigrum), e 172 (rubrum), drucktinte: lacca, propylenglycolum, kalii hydroxidum, e 172 (nigrum), ammoniae solutio concentrata, pro capsula corresp. natrium 0.525 mg. - symptomatische obstruktive hypertrophe kardiomyopathie - synthetika
camzyos 5 mg capsule rigide
bristol-myers squibb sa - mavacamtenum - capsule rigide - mavacamtenum 5 mg, silica colloidalis hydrica, mannitolum, hypromellosum, carmellosum natricum conexum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, propylenglycolum, kalii hydroxidum, e 172 (nigrum), ammoniae solutio concentrata, pro capsula corresp. natrium 1.05 mg. - symptomatische obstruktive hypertrophe kardiomyopathie - synthetika
camzyos 10 mg capsule rigide
bristol-myers squibb sa - mavacamtenum - capsule rigide - mavacamtenum 10 mg, silica colloidalis hydrica, mannitolum, hypromellosum, carmellosum natricum conexum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (rubrum), drucktinte: lacca, propylenglycolum, kalii hydroxidum, e 172 (nigrum), ammoniae solutio concentrata, pro capsula corresp. natrium 0.84 mg. - symptomatische obstruktive hypertrophe kardiomyopathie - synthetika
camzyos 15 mg capsule rigide
bristol-myers squibb sa - mavacamtenum - capsule rigide - mavacamtenum 15 mg, silica colloidalis hydrica, mannitolum, hypromellosum, carmellosum natricum conexum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (nigrum), drucktinte: lacca, propylenglycolum, kalii hydroxidum, e 172 (nigrum), ammoniae solutio concentrata, pro capsula corresp. natrium 1.26 mg. - symptomatische obstruktive hypertrophe kardiomyopathie - synthetika
camzyos
bristol-myers squibb pharma eeig - mavacamten - cardiomyopathy, hypertrophic - altri preparati cardiaci - treatment of symptomatic obstructive hypertrophic cardiomyopathy.